Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;394(5):839-852.
doi: 10.1007/s00210-021-02085-3. Epub 2021 Apr 16.

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020

Gizem Kayki-Mutlu  1 , Martin C Michel  2
Affiliations
Review

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020

Gizem Kayki-Mutlu et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 May.

Abstract

While the COVID-19 pandemic also affected the work of regulatory authorities, the US Food and Drug Administration approved a total of 53 new drugs in 2020, one of the highest numbers in the past decades. Most newly approved drugs related to oncology (34%) and neurology (15%). We discuss these new drugs by level of innovation they provide, i.e., first to treat a condition, first using a novel mechanisms of action, and "others." Six drugs were first in indication, 15 first using a novel mechanism of action, and 32 other. This includes many drugs for the treatment of orphan indications and some for the treatment of tropical diseases previously neglected for commercial reasons. Small molecules continue to dominate new drug approvals, followed by antibodies. Of note, newly approved drugs also included small-interfering RNAs and antisense oligonucleotides. These data show that the trend for declines in drug discovery and development has clearly been broken.

Keywords: FDA; First-in-class; First-in-indication; New drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–684. - PMC - PubMed
    1. Abraham B, Megaly M, Sous M, Fransawyalkomos M, Saad M, Fraser R, Topf J, Goldsmith S, Simegn M, Bart B, Azzo Z, Mesiha N, Sharma R. Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol. 2020;125:92–99. - PubMed
    1. Alkhodaidi ST, Al Hawsawi KA, Alkhudaidi IT, Magzoub D, Abu-Zaid A. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: a systematic review and meta-analysis of randomized placebo-controlled trials. Dermatol Ther. 2021;34:e14609. - PubMed
    1. Altcheh J, Castro L, Dib JC, Grossmann U, Huang E, Moscatelli G, Pinto Rocha JJ, Ramírez TE. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO) PLoS Negl Trop Dis. 2021;15:e0008912. - PMC - PubMed
    1. Alzofon N, Jimeno A. Capmatinib for non-small cell lung cancer. Drugs Today (Barc) 2021;57:17–25. - PubMed